Literature DB >> 19110306

Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker.

Marina Devetzi1, Andreas Scorilas, Evangelos Tsiambas, Mansoureh Sameni, Stelios Fotiou, Bonnie F Sloane, Maroulio Talieri.   

Abstract

OBJECTIVE: Lysosomal cysteine protease Cathepsin-B has been implicated in the progression of various human tumours. We examined Cathepsin-B protein levels in endometrial carcinoma patients-mainly post-menopausal-and investigated their possible association with clinical and pathological parameters in order to assess Cathepsin-B's significance as a potential tumour biomarker.
METHODS: The indirect immunoperoxidase method was used for Cathepsin-B immunohistochemical staining of 64 paraffin-embedded endometrial tumour tissues, having follow-up period of 18-240 months. Steroid hormone receptors were measured as well. Tissue samples were staged following the FIGO criteria.
RESULTS: Positive Cathepsin-B immunostaining was observed in 27 patients (42.2%) and was significantly associated with the FIGO stage of the disease (p=0.006), as well as cervical and stromal invasion (p=0.001 and p=0.037, respectively) and progesterone receptor status (p=0.027). Positive Cathepsin-B expression was also inversely related to Disease-free Survival (p=0.034) and Overall Survival (p=0.035) in univariate analysis, as well as in multivariate analysis (p=0.022 and p=0.035, respectively).
CONCLUSION: Increased Cathepsin-B expression was found to be predictive of more aggressive tumour behaviour over time and can be regarded as an unfavourable and independent tumour marker for endometrial cancer patients with a long follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110306     DOI: 10.1016/j.ygyno.2008.10.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma.

Authors:  Israel Zighelboim; Andrew J Reinhart; Feng Gao; Amy P Schmidt; David G Mutch; Premal H Thaker; Paul J Goodfellow
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

2.  Controversies in the management of endometrial carcinoma.

Authors:  Ying Zhang; Jian Wang
Journal:  Obstet Gynecol Int       Date:  2010-06-22

3.  The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  Molecules       Date:  2012-03-26       Impact factor: 4.411

4.  Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression.

Authors:  Sherif A Ibrahim; Eslam A El-Ghonaimy; Hebatallah Hassan; Noha Mahana; Mahmoud Abdelbaky Mahmoud; Tahani El-Mamlouk; Mohamed El-Shinawi; Mona M Mohamed
Journal:  J Adv Res       Date:  2016-06-30       Impact factor: 10.479

5.  A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer.

Authors:  Fangfei Li; Jun Lu; Jin Liu; Chao Liang; Maolin Wang; Luyao Wang; Defang Li; Houzong Yao; Qiulong Zhang; Jia Wen; Zong-Kang Zhang; Jie Li; Quanxia Lv; Xiaojuan He; Baosheng Guo; Daogang Guan; Yuanyuan Yu; Lei Dang; Xiaohao Wu; Yongshu Li; Guofen Chen; Feng Jiang; Shiguo Sun; Bao-Ting Zhang; Aiping Lu; Ge Zhang
Journal:  Nat Commun       Date:  2017-11-09       Impact factor: 14.919

6.  Cathepsin B expression in colorectal cancer in a Middle East population: Potential value as a tumor biomarker for late disease stages.

Authors:  Maha-Hamadien Abdulla; Mansoor-Ali Valli-Mohammed; Khayal Al-Khayal; Abdulmalik Al Shkieh; Ahmad Zubaidi; Rehan Ahmad; Khalid Al-Saleh; Omar Al-Obeed; James McKerrow
Journal:  Oncol Rep       Date:  2017-04-18       Impact factor: 3.906

7.  Investigating Novel Genes Potentially Involved in Endometrial Adenocarcinoma using Next-Generation Sequencing and Bioinformatic Approaches.

Authors:  Feng-Hsiang Tang; Wei-An Chang; Eing-Mei Tsai; Ming-Ju Tsai; Po-Lin Kuo
Journal:  Int J Med Sci       Date:  2019-09-07       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.